Oncology

Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis

Cellenkos has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational CK0804 regulatory T cell (Treg) therapy to treat myelofibrosis, a rare blood cancer.

J&J receives FDA approval for lung cancer therapy

Johnson & Johnson (J&J) has received the US Food and Drug Administration (FDA) approval for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a subcutaneously (SC) administered therapy to treat patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).

Takeda and Innovent fulfil close conditions for ADC and IO therapies

Takeda and Innovent have closed their global partnership for next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, following the fulfilment of all closing conditions.

Johnson & Johnson to acquire Halda Therapeutics for $3.05bn

Johnson & Johnson (J&J) has signed a definitive agreement for the acquisition of Halda Therapeutics (Halda) in a $3.05bn cash deal.

Myrio Therapeutics announces partnership for immunotherapy development

Myrio Therapeutics has announced a collaborative partnership with NYU Langone Health and the University of Pennsylvania Perelman School of Medicine to expedite next-generation T cell immunotherapeutics development for solid tumours.

Citius Oncology finalises McKesson deal for Lymphir distribution

Citius Oncology has entered into an agreement with McKesson for the distribution of Lymphir (denileukin diftitox-cxdl).

Avenzo Therapeutics secures $60m in series B funding for oncology therapies

Avenzo Therapeutics, a clinical-stage biotechnology company, has closed a $60m series B financing round to advance the development of its oncology drug candidates.

BeOne Medicines receives EC approval for Brukinsa tablet formulation

BeOne Medicines has received the European Commission (EC) approval for Brukinsa’s (zanubrutinib) new film-coated tablet formulation for all approved indications.

Halda receives FDA fast track status for HLD-0915 to treat prostate cancer

Halda Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its lead development candidate, HLD-0915, aimed at treating metastatic castration-resistant prostate cancer (mCRPC).